The exploratory study to determine optimum dosing of Axitinib (tyrosine kinase inhibitor) with pharmacokinetic analysis for patients with metastatic renal cell carcinoma
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- 10 Feb 2018 Results (n=44) assessing the relationship between axitinib pharmacogenetics and clinical efficacy/adverse events presented at the 2018 Genitourinary Cancers Symposium
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 20 Aug 2013 New trial record